afatinib Articles
Boehringer Ingelheim's afatinib NDA gets priority review in USA
16 January 2013
Boehringer Ingelheim highlights robust respiratory R&D pipeline; announces investment
1 November 2012
US oncologists' perceptions of Roche's Perjeta very promising
7 September 2012
Boehringer Ingelheim’s afatinib improves progression free survival in lung cancer patients
15 October 2010
Showing 1-7 of 7 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
